ECSP088378A - Derivados de piperazina útiles como antagonistas de ccr5 - Google Patents
Derivados de piperazina útiles como antagonistas de ccr5Info
- Publication number
- ECSP088378A ECSP088378A EC2008008378A ECSP088378A ECSP088378A EC SP088378 A ECSP088378 A EC SP088378A EC 2008008378 A EC2008008378 A EC 2008008378A EC SP088378 A ECSP088378 A EC SP088378A EC SP088378 A ECSP088378 A EC SP088378A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- hydrogen
- substituted phenyl
- naphthyl
- treatment
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001624 naphthyl group Chemical group 0.000 abstract 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000001326 naphthylalkyl group Chemical group 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Se revela el uso de antagonistas de CCR5 de la fórmula Io de una sal farmacéuticamente aceptable de los mismos, en donde R es fenilo opcionalmente sustituido, piridilo, tiofenilo o naftilo; R1 es hidrógeno o alquilo; R2 es fenilo sustituido, heteroarilo sustituido, naftilo, fluorenilo, difenilmetilo o fenil- opcionalmente sustituido o heteroaril-alquilo; R3 es hidrógeno, alquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, o fenilo opcionalmente sustituido, fenilalquilo, naftilo, naftilalquilo, heteroarilo o heteroarilalquilo; R4, R5 y R7 son hidrógeno o alquilo; R6 es hidrógeno, alquilo o alquenilo; para el tratamiento de HIV, rechazo de trasplante de órganos sólidos, enfermedad de injerto versus huésped, artritis, artritis reumatoide, enfermedad inflamatoria del intestino, dermatitis atópica, psoriasis, asma, alergias o esclerosis múltiple, así como también nuevos compuestos, composiciones farmacéuticas que los comprenden, y la combinación de antagonistas de CCR5 de la invención en combinación con agentes antivirales útiles en el tratamiento del VIH o con agentes útiles en el tratamiento de enfermedades inflamatorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/255,643 US7825121B2 (en) | 1999-05-04 | 2005-10-21 | Piperazine derivatives useful as CCR5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088378A true ECSP088378A (es) | 2008-05-30 |
Family
ID=37872167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008378A ECSP088378A (es) | 2005-10-21 | 2008-04-17 | Derivados de piperazina útiles como antagonistas de ccr5 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7825121B2 (es) |
| EP (1) | EP1951708B1 (es) |
| JP (2) | JP2009512705A (es) |
| KR (1) | KR20080058486A (es) |
| CN (1) | CN101326178A (es) |
| AR (1) | AR058105A1 (es) |
| AU (1) | AU2006306491B2 (es) |
| BR (1) | BRPI0617731A2 (es) |
| CA (1) | CA2626565A1 (es) |
| EC (1) | ECSP088378A (es) |
| IL (1) | IL190902A0 (es) |
| NO (1) | NO20082297L (es) |
| PE (1) | PE20070711A1 (es) |
| RU (1) | RU2008119652A (es) |
| TW (1) | TW200800234A (es) |
| WO (1) | WO2007050375A2 (es) |
| ZA (1) | ZA200803454B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005101838A2 (en) * | 2004-04-13 | 2005-10-27 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| AU2006335042A1 (en) * | 2005-10-21 | 2007-07-19 | Glaxo Group Limited | Compounds |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| CA2829219C (en) | 2011-03-09 | 2021-03-16 | Richard G. Pestell | Prostate cancer cell lines, gene signatures and uses thereof |
| GB201118876D0 (en) | 2011-11-01 | 2011-12-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9453836B2 (en) | 2012-05-14 | 2016-09-27 | Richard G. Pestell | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis |
| WO2016094011A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Crystal forms of a ccr5 antagonist |
| US12459808B2 (en) | 2021-09-13 | 2025-11-04 | Kabushiki Kaisha Toshiba | Sensor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103214T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperazin trevleri. |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| CA2442210C (en) | 2001-03-29 | 2009-09-08 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
-
2005
- 2005-10-21 US US11/255,643 patent/US7825121B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 CN CNA2006800462485A patent/CN101326178A/zh active Pending
- 2006-10-18 WO PCT/US2006/040636 patent/WO2007050375A2/en not_active Ceased
- 2006-10-18 JP JP2008536749A patent/JP2009512705A/ja active Pending
- 2006-10-18 EP EP06826151.0A patent/EP1951708B1/en active Active
- 2006-10-18 BR BRPI0617731-0A patent/BRPI0617731A2/pt not_active IP Right Cessation
- 2006-10-18 CA CA002626565A patent/CA2626565A1/en not_active Abandoned
- 2006-10-18 RU RU2008119652/04A patent/RU2008119652A/ru not_active Application Discontinuation
- 2006-10-18 AU AU2006306491A patent/AU2006306491B2/en not_active Ceased
- 2006-10-18 KR KR1020087011479A patent/KR20080058486A/ko not_active Withdrawn
- 2006-10-19 PE PE2006001267A patent/PE20070711A1/es not_active Application Discontinuation
- 2006-10-19 AR ARP060104564A patent/AR058105A1/es not_active Application Discontinuation
- 2006-10-20 TW TW095138842A patent/TW200800234A/zh unknown
-
2008
- 2008-04-15 IL IL190902A patent/IL190902A0/en unknown
- 2008-04-17 EC EC2008008378A patent/ECSP088378A/es unknown
- 2008-04-18 ZA ZA200803454A patent/ZA200803454B/xx unknown
- 2008-05-20 NO NO20082297A patent/NO20082297L/no not_active Application Discontinuation
-
2012
- 2012-01-17 JP JP2012007201A patent/JP2012072195A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW200800234A (en) | 2008-01-01 |
| US20060105964A1 (en) | 2006-05-18 |
| CA2626565A1 (en) | 2007-05-03 |
| EP1951708B1 (en) | 2013-11-20 |
| AU2006306491B2 (en) | 2012-12-13 |
| WO2007050375A2 (en) | 2007-05-03 |
| KR20080058486A (ko) | 2008-06-25 |
| BRPI0617731A2 (pt) | 2011-08-02 |
| RU2008119652A (ru) | 2009-11-27 |
| IL190902A0 (en) | 2008-11-03 |
| CN101326178A (zh) | 2008-12-17 |
| PE20070711A1 (es) | 2007-08-11 |
| ZA200803454B (en) | 2009-04-29 |
| EP1951708A2 (en) | 2008-08-06 |
| US7825121B2 (en) | 2010-11-02 |
| WO2007050375A3 (en) | 2007-06-14 |
| NO20082297L (no) | 2008-07-21 |
| JP2009512705A (ja) | 2009-03-26 |
| JP2012072195A (ja) | 2012-04-12 |
| AU2006306491A1 (en) | 2007-05-03 |
| AR058105A1 (es) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088378A (es) | Derivados de piperazina útiles como antagonistas de ccr5 | |
| CO5170523A1 (es) | Derivados de piperazina utiles como antagonistas de ccr5 | |
| UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
| BR0010607A (pt) | Derivados de piperidina úteis como antagonistas de ccr5 | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| BRPI0612888B8 (pt) | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| CR8744A (es) | Compuestos terapeuticos | |
| AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| GEP20135863B (en) | Substituted piperidines as ccr3 antagonists | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| CY1105198T1 (el) | Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv) | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| DOP2011000338A (es) | Compuestos carboxamida y su uso como inhibidores de calpaina | |
| UY29198A1 (es) | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones | |
| UY29009A1 (es) | Nuevos derivados de pirimidina, sales y solvatos farmaccuticamente aceptables de los mismos, composiciones, procedimientos para su preparacinn y uso. | |
| UY30577A1 (es) | Derivados de éter diarilico y usos de los mismos | |
| RU2009142997A (ru) | 4-алкоксипиридазиновые производные в качестве быстро диссоциирующихся антагонистов рецептора 2 допамина | |
| AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
| HRP20060127A2 (en) | Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist | |
| AR082962A1 (es) | Derivados de quinoxalina y composiciones farmaceuticas |